NCT06881888View on ClinicalTrials.gov

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Diabetic Macular Edema
Interventions
DRUG

Octreotide (drug)

Participants will administer the DDM-octreotide nasal spray without priming in one nostril three times a day.

DRUG

Placebo

Participants will administer the placebo nasal spray without priming in one nostril three times a day.

Trial Locations (1)

35243

The University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER